○Ming-Huang Chen1, Nai-Jung Chiang2, Li-Yuan Bai3, Chien-Jui Huang4, San-Chi Chen1, Chin-Fu Hsiao2, Yan-Shen Shan4, Yung-Yeh Su2, Li‐Tzong Chen2 (1.Department of Oncology, Taipei Veterans General Hospital, 2.National Institute of Cancer Research, National Health Research Institutes, 3.China Medical University Hospital, 4.National Cheng Kung University)
Session information
Oral Session
[O17] Oral Session 17 Hepatobiliary / Pancreatic Cancer
【E】
Sat. Feb 19, 2022 10:10 AM - 11:30 AM Room 10 (Royal Room, 1F, The Prince Kyoto Takaragaike)
Chair:Masashi Kanai(Department of Therapeutic Oncology, Kyoto University),Naoki Sasahira(Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
Discussant:Satoshi Kobayashi(Department of Gastroenterology, Kanagawa Cancer Center)
○Naminatsu Takahara1, Yousuke Nakai2, Toshio Fujisawa3, Takashi Sasaki4, Yuji Morine5, Kazuo Watanabe6, Makoto Ueno7, Tatsuya Ioka8, Masashi Kanai9, Shunsuke Kondo10, Naohiro Okano11, Hiroyuki Isayama3, Kazuhiko Koike1 (1.Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 2.Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, 3.Department of Gastroenterology, Graduate School of Medicine, The Juntendo University, 4.Division of Hepatobiliary and Pancreatic Medical Oncology, Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 5.Department of Surgery, Tokushima University Graduate School of Biomedical Sciences, 6.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 7.Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 8.Oncology Center, Yamaguchi University Hospital, 9.Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 10.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital Tokyo, 11.Department of Medical Oncology, Kyorin University, Faculty of Medicine)
○Makoto Ueno1, Ghassan K. Abou-Alfa2,3, Vaibhav Sahai4, Antoine Hollebecque5, Gina Vaccaro6, Davide Melisi7, Raed Al-Rajabi8, Andrew Scott Paulson9, Mitesh J. Borad10, David Gallinson11, Adrian G. Murphy12, Do-Youn Oh13, Efrat Dotan14, Daniel V. Catenacci15, Eric Van Cutsem16, Christine Lihou17, Huiling Zhen17, Luis Féliz18, Arndt Vogel19 (1.Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 2.Department of Medicine, Memorial Sloan Kettering Cancer Center, 3.Weill Medical College at Cornell University, 4.Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, 5.Department of Adult Medicine, Gustave Roussy, 6.Providence Cancer Center Oncology and Hematology Care Clinic, 7.Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, 8.Department of Internal Medicine, Division of Hematology/Oncology, University of Kansas Cancer Center, 9.Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, 10.Department of Internal Medicine, Mayo Clinic Cancer Center, 11.Department of Hematology/Oncology, Morristown Memorial Hospital, Carol Cancer Center, 12.Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 13.Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 14.Department of Hematology/Oncology, Fox Chase Cancer Center, 15.Department of Medicine, University of Chicago Medicine, 16.Department of Digestive Oncology, University Hospitals Leuven and KU Leuven, 17.Incyte Corporation, 18.Incyte Biosciences International Sàrl, 19.Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School)
○Masafumi Ikeda1, Chigusa Morizane2, Makoto Ueno3, Kentaro Sudo4, Yoshinori Hirashima5, Masataka Kuroda5, Yuki Fukuyama5, Takuji Okusaka2, Junji Furuse6 (1.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 2.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 3.Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 4.Division of Gastroenterology, Chiba Cancer Center, 5.Clinical Development Headquarters, Ono Pharmaceutical Co., Ltd., 6.Department of Medical Oncology, Kyorin University Faculty of Medicine)
○Sadahisa Ogasawara1, Masafumi Ikeda2, Tatsuya Yamashita3, Masatoshi Kudo4, Yoshitaka Inaba5, Manabu Morimoto6, Kaoru Tsuchiya7, Satoshi Shimizu8, Yasushi Kojima9, Atsushi Hiraoka10, Kazuhiro Nouso11, Hiroshi Aikata12, Kazushi Numata13, Tosiya Sato14, Takuji Okusaka15, Junji Furuse16 (1.Department of Gastroenterology, Graduate School of Medicine, Chiba University, 2.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 3.Department of Gastroenterology, Kanazawa University Hospital, 4.Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 5.Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 6.Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, 7.Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 8.Department of Gastroenterology, Saitama Cancer Center, 9.Department of Gastroenterology, National Center for Global health and Medicine Center Hospital, 10.Gastroenterology Center, Ehime Prefectural Central Hospital, 11.Department of Gastroenterology, Okayama City Hospital, 12.Department of Gastroenterology and Metabolism, Hiroshima University, 13.Gastroenterological Center, Yokohama City University Medical Center, 14.Department of Biostatistics, Kyoto University School of Public Health, 15.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 16.Department of Medical Oncology, Kyorin University Faculty of Medicine)